



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/631,613	08/04/2000	Holly Hogrefe	4121.0116-07	6689

7590 01/12/2005

Finnegan Henderson Farabow Garrett & Dunner LLP  
Stanford Research Park  
700 Hansen Way  
Palo Alto, CA 94304

EXAMINER

WILDER, CYNTHIA B

ART UNIT PAPER NUMBER

1637

DATE MAILED: 01/12/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<p align="center"><b>Office Action Summary</b></p>	<p><b>Application No.</b></p> <p>09/631,613</p>	<p><b>Applicant(s)</b></p> <p>HOGREFE ET AL.</p>	
	<p><b>Examiner</b></p> <p>Cynthia B. Wilder, Ph.D.</p>	<p><b>Art Unit</b></p> <p>1637</p>	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 18 October 2004.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 69,70,72 and 74 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 69,70,72 and 74 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 18 October 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| <p>1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)</p> <p>2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)</p> <p>3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br/> Paper No(s)/Mail Date _____.</p> | <p>4) <input type="checkbox"/> Interview Summary (PTO-413)<br/> Paper No(s)/Mail Date. _____.</p> <p>5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p> <p>6) <input type="checkbox"/> Other: _____.</p> |
|---|---|

**FINAL ACTION**

1. Applicant's amendment filed on October 18, 2004 is acknowledged and has been entered. Claims 69, 70, 72 and 74 have been amended. Claims 1-68, 71, 73 and 75-94 have been canceled. Claims 69, 70, 72 and 74 are currently pending. All of the amendments and remarks have been thoroughly reviewed and considered but are deemed moot in view of the new ground(s) of rejections based on Applicant's amendment to the claims. Any rejection not reiterated in this action has been withdrawn as being obviated by the amendment of the claims.

**This action is made FINAL**

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

***Previous Rejections***

3. The claim rejection under 35 USC 112 first paragraph directed to claims 40-44 are withdrawn in view of Applicant's cancellation of the claims. The claim rejections under 35 USC 112 second paragraph directed to claims 69-70, 72 and 74 are withdrawn in view of Applicant's amendment. The prior art rejection under 35 USC 102 directed to claims 40-44 are withdrawn in view of Applicant's cancellation of the claims.

**NEW GROUND(S) OF REJECTION**

**THE NEW GROUND(S) OF REJECTIONS WERE NECESSITATED BY APPLICANT'S AMENDMENT OF THE CLAIMS:**

***Claim Rejections - 35 USC § 112***

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1637

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 69, 70, 72 and 74 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of enhancing a nucleic acid polymerase comprising (a) forming a nucleic acid polymerase reaction composition comprising (i) a nucleic acid (ii) at least one nucleic acid polymerase, wherein said polymerase is Pfu DNA polymerase and....., it does not reasonably provide enablement for a method of enhancing a nucleic acid polymerase reaction comprising: forming a nucleic acid polymerase reaction comprising: (i) a nucleic acid and any nucleic acid polymerase and..... . The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

The first paragraph of section 112 requires the specification describe how to make and use the invention. There are many factors to be considered when determining whether there is sufficient evidence to support determination that a disclosure does not satisfy the enablement requirements and whether any necessary experimentation is undue (*See In re Wands*, 858 F. 2d 731, 8 USPQ2d 1400, 1404, (Fed. Cir. 1988)). These factors include, but are not limited to:

*I. Quantity of Experimentation Necessary*

The claimed invention is drawn to a method of a method of enhancing a nucleic acid polymerase reaction comprising (a) forming a nucleic acid polymerase reaction composition comprising: (i) a nucleic acid; (ii) at least one nucleic acid polymerase, and (iii) a P45 protein, wherein the P45 protein is in monomeric, dimeric, or multimeric form, and wherein the p45 protein is produced from a cell containing a DNA construct comprising a sequence encoding

Art Unit: 1637

polymerase enhancing factor protein P45 operably linked to an expression vector, and (b) incubating the nucleic acid polymerase reaction composition under conditions allowing a nucleic acid polymerase reaction, wherein the P45 protein enhances the nucleic acid polymerase reaction. The claims are also drawn to a method for controlling the activity of a polymerase in a nucleic acid polymerase reaction, comprising: (a) forming a nucleic acid polymerase reaction composition: (i) a nucleic acid; (ii) at least one nucleic acid polymerase, and (iii) a polymerase enhancing factor activity, wherein the polymerase enhancing factor activity changes the amount of dUTP present or generated during the reaction, and (b) incubating the nucleic acid polymerase reaction composition under conditions allowing a nucleic acid polymerase reaction, wherein changing the amount of dUTP present or generated during the reaction controls the activity of the polymerase in the polymerization reaction.

The specification at page 5 defines "a polymerase enhancing activity" as the ability to increase the rate, fidelity and/or yield of a nucleic acid polymerization reaction mediated by a nucleic acid polymerase, or to expand or alter the range of conditions under which such reaction does or may proceed. The specification broadly teaches that the term "polymerase enhancing factor (PEF)" includes purified naturally occurring polymerase enhancing factors and wholly or partially synthetic copies or active analogs thereof.

In the Summary of the Invention and Detailed Description beginning at page 5, the specification discloses that extracts of *Pfu* cells are provided that enhance the activity of *Pfu* DNA polymerase as well as human dUTPase, which enhances polymerase activity. Further the specification teaches that polymerase enhancing factor complexes such as e.g., the P300 complex from *Pfu* cells sample extracts, which comprises protein components namely the P50 protein and

Art Unit: 1637

P45 protein, function to enhance the activity of polymerase. Likewise the specification discloses that other Pfu proteins having molecule weight between 42 and 60 kD alone or in combination functions to enhance polymerase activity. The examples beginning at page 20 discloses wherein polymerase enhancing factor (PEF) activity was screened in Pfu DSM 3638 cells, identified, purified or partially purified and tested for polymerase enhancing factor in replication reactions, amplification reactions, cloning and mutagenesis assays. The specification however does not teach or describe a method of enhancing a nucleic acid polymerase reaction or method of controlling the activity of any of the numerous nucleic acid polymerases by forming a nucleic acid polymerase reaction composition comprising a nucleic acid and any of the numerous nucleic acid polymerase along with a P45 protein or a polymerase enhancing factor activity. Likewise, the specification provides no teaching wherein any extract, protein, complex, mixture or analog that may have a polymerase enhancing factor activity as claimed in claim 72 is capable of function in the method for controlling the activity of a polymerase. Nowhere in the specification is there an indication that any of the numerous nucleic acid polymerase known in the art (see T.A Brown, Molecular Biology LabFax, pages 140-153, December 1991), such as e.g., Kornberg polymerase, Klenow fragment, T4 DNA polymerase, T7 DNA polymerase, Taq DNA polymerase, Micrococcal DNA polymerase, Alpha DNA polymerase, *Ecoli* RNA polymerase, SP6 RNA polymerase, T3 RNA polymerase, T7 RNA polymerase, RNA polymerase II, Poly(A) polymerase, exo-Vent polymerase and/or etc., besides Pfu DNA polymerase, is capable of being enhanced when combined in a nucleic acid polymerase composition comprising a polymerase enhancing factor P45 protein or polymerase enhancing factor activity. The specification provides no information to allow one of ordinary skill in the art to make or use the claimed method using

Art Unit: 1637

the large number of undisclosed polymerase sequences and unlimited extracts, proteins, complexes, mixtures or analogs that may have a polymerase enhancing factor activity. Undue burden would be required of the practitioner as the invention encompasses numerous nucleic acid molecules and protein molecules that may or may not be functional in the claimed methods.

## *II. Amount of Direction and Guidance and Presence and absence of Working examples*

The specification does not provide a method of enhancing a nucleic acid polymerase reaction by forming a nucleic acid polymerase reaction composition that bears a reasonable correlation to the entire scope of the claims. The examples beginning at 20 to page 68 lack information concerning using any nucleic acid polymerase known in the art and/or any polymerase enhancing factor activity which may comprise any and every possible extract, protein, protein complex, mixtures. There is no guidance in the specification for detecting any and every possible extract, protein, complex, mixture of proteins or analogs thereof which may or may not be functional for controlling the activity of a polymerase. Additionally, there is no direction or guidance given to substantiate what effect any nucleic acid polymerase would have in the presence of a polymerase enhancing factor P45 protein or polymerase enhancing factor activity without further experimentation for the broad scope of the claims.

## *III. Level of predictability or unpredictability in the art*

The specification has not enabled a method of enhancing any nucleic acid polymerase or a method for controlling the activity of any polymerase in a polymerase reaction that is commensurate fully in scope. While the molecular biology techniques utilized are known in the

Art Unit: 1637

art, it is not routine in the art to screen multitudes nucleic acid polymerase reaction compositions, to determine nucleic acid polymerase enhancing activity. Additionally, the results of any screening or modification thereof is unpredictable since a reasonable expectation of success is limited by a lack of knowledge concerning the functionality of all of the nucleic acid molecules and protein molecules encompassed by the claimed invention.. Therefore without sufficient knowledge and guidance, determining a polymerase enhancing composition as claimed is unpredictable. Thus, for all of the foregoing reasons, undue experimentation is necessary for one of skill in the art to obtain the claimed invention.

### *Conclusion*

6. No claims are allowed. However, the claims are free of the prior art. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.



Art Unit: 1637


7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia B. Wilder, Ph.D. whose telephone number is (571) 272-0791. The examiner works a flexible schedule and can be reached by phone and voice mail. Alternatively, a request for a return telephone call may be emailed to [cynthia.wilder@uspto.gov](mailto:cynthia.wilder@uspto.gov). Since email communications may not be secure, it is suggested that information in such request be limited to name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

  
KENNETH R. HORLICK, PH.D.  
PRIMARY EXAMINER  
1/5/05